Pain Therapeutics, King get priority review for pain drug
NEW YORK (MarketWatch) — Pain Therapeutics Inc. and King
Pharmaceuticals Inc. said Tuesday that the U.S. Food and Drug Administration granted priority review to its new drug application for Remoxy pain medication. The FDA is expected to complete its review within six months of the application’s submission, which in this case is June 10. The drugmakers described Remoxy as “abuse-resistant, controlled-release oxycodone for moderate-to-severe chronic pain.”
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
